PaxMedica Inc. PXMD Archives - Page 3 of 6

FridayJan 26, 2024 1:34 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD

PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD… Focused on evaluating the efficacy and safety of suramin intravenous infusions, the study’s 10 mg/kg suramin arm displayed promising results in improving core symptoms of ASD, showcasing statistically significant improvements in the Clinical Global Impressions-Improvement (‘CGI-I’) scale…

TuesdayJan 16, 2024 11:15 am

InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study

In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder (“ASD”), initially published in the Annals of General Psychiatry. This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD. The study, a comprehensive 14-week randomized, double-blind, placebo-controlled trial, enrolled 52 boys aged 4–15 years with moderate to severe ASD. Focused on evaluating the efficacy and safety of…

FridayJan 12, 2024 1:09 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on developing novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “While ASD is not uncommon, there are no pharmaceutical treatments approved to treat the disorder, only to manage the symptoms – which creates an unmet need in the industry… PaxMedica is on a mission to help, reduce and modulate some of the more challenging aspects of ASD. The company hopes to enable people with autism to integrate their behavior with others more successfully and improve their quality of life,”…

ThursdayDec 21, 2023 4:52 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Files 8-K Following Nasdaq Compliance Achievement

In a significant corporate update, PaxMedica (NASDAQ: PXMD) today filed an 8-K with the Securities and Exchange Commission, disclosing its successful compliance with Nasdaq’s minimum equity requirements. Journey Towards Compliance PaxMedica's compliance journey began on December 6, 2022, when Nasdaq noted its inability to meet the Minimum Market Value of Listed Securities Requirement of $35 million over 30 days. PaxMedica faced potential delisting in June 2023 but successfully appealed and, after a Nasdaq Hearings Panel review, received an exception to remain listed, subject to meeting specific financial criteria. Achieving and Announcing Compliance With the recent notification from Nasdaq, PaxMedica has…

MondayDec 18, 2023 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline

The CDC estimates 1 out of 36 children in the United States have been diagnosed with Autism Spectrum Disorder – with a therapeutic market potential of $3.42 billion by 2030 PaxMedica’s mission is to help eliminate, reduce, or modulate the troublesome aspects of ASD, an unmet medical need in the industry CEO Howard Weisman shared important updates and achievements in the company’s pipeline, financial outlook, and future vision In a 2020 report released by the Centers for Disease Control and Prevention (“CDC”), it was estimated that 1 out of 36 children had been diagnosed with autism spectrum disorder (“ASD”) in…

WednesdayDec 06, 2023 1:39 pm

QualityStocksNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has released a fireside chat video with CEO and chair Howard Weisman. During the company update video, Weisman outlines the company’s recent achievement and reiterates PaxMedica’s focus on developing groundbreaking therapies and transformative solutions. Specifically, Weisman provided a summary of the company’s Oct. 25, 2023, FDA Type-B meeting, including the regulatory pathway for HAT-PAX-101. He also discussed the company’s successful $7 million public offering and the recent acquisition of suramin research assets from Rediscovery Life Sciences (“RLS”) as well as provided updates on the phase 3 trial…

WednesdayDec 06, 2023 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study

During the live type-B meeting, PaxMedica discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One HAT, also called African Sleeping Sickness The FDA is allowing PaxMedica to use previous data from early tests of suramin to begin developing the drug for use in current cases of HAT PaxMedica received constructive feedback, which will aid in completing the remaining work necessary to file a New Drug Application (“NDA”), expected in the second half of 2024 The global ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42…

TuesdayDec 05, 2023 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Closes Public Offering of Approximately $7 Million and Continues Pursuing ASD Pipeline

PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million The company intends to use the proceeds to pay an outstanding promissory note, advance development programs, and general corporate purposes PaxMedica received constructive feedback from its type-B meeting with the FDA, which will aid in completing the remaining paperwork necessary to file a New Drug Application The company is currently working on commercial lots of PAX-101, which are expected during the first half of 2024, for the New Drug Application, which is expected to be filed during the second…

MondayDec 04, 2023 2:52 pm

QualityStocksNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Recent H.C. Wainwright & Co. Research Report with ‘Buy’ Rating, $3 PT

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent H.C. Wainwright & Co. research report. The report “is initiating coverage on PaxMedica, an emerging firm developing novel formulations of suramin for treatment of neurological disorders with intractable symptoms,” which is “attacking autism with a novel approach.” The report noted that PaxMedica was the first company to design and execute a controlled clinical study based on the agency’s inputs, with top-line data based on retrospective analysis of medical records being presented in November 2023 that “showed PAX-101 (intravenous suramin) clinical meaningfulness in…

MondayNov 27, 2023 12:36 pm

QualityStocksNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has closed its previously announced public offering. The offering was comprised of 5,384,615 shares of common stock (or common stock equivalents in lieu thereof) and warrants; the shares were offered at $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants also had an exercise price of $1.30 per share, as well as being exercisable immediately upon issuance; the warrants will expire five years after the initial exercise date. The company noted that total gross proceeds for the…

Site Search

Company Search

Tag: PaxMedica Inc. PXMD